Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Medical Information FSGS

FILSPARI (sparsentan): Effect on Estimated Glomerular Filtration Rate (eGFR) in FSGS

Learn more
Medical Information FSGS

FILSPARI (sparsentan): Dosing and Administration in Clinical Trials of FSGS

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – 2-Year Results from the Phase 3 DUPLEX Study Published in the NEJM

Learn more
Posters FSGS

Understanding the Impact of Immunoglobulin ANephropathy (IgAN) and Focal Segmental Glomerulosclerosis (FSGS) on Patients and Care-Partners Study(HONUS): Updated Results for IgAN in the United States (US)

Learn More
Medical Information FSGS

EPPIK (Phase 2 Study): Treatment in Pediatric Patients With Proteinuric Glomerular Diseases

Learn more
Medical Information FSGS

Phase 2 DUET Study Published in the Journal of the American Society of Nephrology

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Effect on Proteinuria in Focal Segmental Glomerulosclerosis

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Pediatric Patients in Sparsentan FSGS Studies

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Hyperkalemia

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Acute Kidney Injury

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Impact on Pregnancy, Lactation, and Fertility

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – DUPLEX (Phase 3 Study): Study Design & Topline Results

Learn more
Medical Information FSGS

FILSPARI (sparsentan) Dual Receptor Antagonism in Renal Pathophysiology and Reduction of Proteinuria

Learn more